ArticleDiscover oncology2026
Target trial emulation of survival outcomes for clinically localized prostate cancer treatments.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ProtecT randomized trial found similar survival between active surveillance (AS), radiotherapy (RT), and radical prostatectomy (PT) in localized prostate cancer (PC), but observational studies yielded conflicting results. This study aims to emulate ProtecT by comparing survival outcomes of men with localized PC undergoing PT or RT versus AS/watchful waiting (WW).
methodsThis target trial emulation study used the Korean Nationwide Health Insurance, Cancer Registry, and Death Registry linkage data (2012-2020). We included men (50-69 years) diagnosed with a first malignant localized PC. Primary outcome was PC-specific death, and secondary outcomes were all-cause death, metastasis, and antidepressant initiation. Two cohorts (PT vs. AS/WW and RT vs. AS/WW) were analyzed using Cox regression to estimate hazard ratios (HRs) with 95% confidence intervals (CIs).
resultsAmong 8,036 localized PC patients, 1,191 PT vs. 1,191 AS/WW and 428 RT vs. 428 AS/WW individuals were identified. During a mean follow-up of 4.4 years, PC-specific death occurred in 2 men (0.2%) in PT and 2 men (0.2%) in AS/WW, and 3 men (0.7%) in RT with 1 man (0.2%) in AS/WW. AS/WW showed comparable risks of PC-specific and all-cause death and metastasis as PT and RT. Compared to AS/WW, PT and RT showed lower risks of antidepressant initiation (HR [95% CI] 0.73 [0.58-0.93] for PT and HR 0.38 [0.24-0.61] for RT, respectively).
conclusionsIn this target trial emulation study, AS/WW showed similar risks of mortality and metastasis as PT and RT, while PT and RT showed favorable outcomes with antidepressant initiation in Asian men with localized PC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.